<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Reserpine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00206</strong>&#160; (APRD00472)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00206/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00206/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00206.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00206.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00206.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00206.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00206.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00206">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(&#8722;)-reserpine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>3,4,5-trimethoxybenzoyl methyl reserpate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Apoplon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hiserpia</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Novoreserpine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Reserfia</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Serpalan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Serpanray</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Serpasil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Demi-Regroton</td><td>Chlorthalidone + reserpine</td></tr><tr><td>Diupres-250</td><td>Chlorothiazide + reserpine</td></tr><tr><td>Diupres-500</td><td>Chlorothiazide + reserpine</td></tr><tr><td>Diutensen-R</td><td>Methyclothiazide + reserpine</td></tr><tr><td>Hydromox R</td><td>Quinethazone + reserpine</td></tr><tr><td>Hydropres 25 Tab</td><td>Hydrochlorothiazide + Reserpine</td></tr><tr><td>Hydropres 50 Tab</td><td>Hydrochlorothiazide + Reserpine</td></tr><tr><td>Regroton</td><td>Chlorthalidone + reserpine</td></tr><tr><td>Renese-R</td><td>Polythiazide + reserpine</td></tr><tr><td>SER-AP-ES Tab</td><td>Hydralazine Hydrochloride + Hydrochlorothiazide + Reserpine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/adrenergic-uptake-inhibitors">Adrenergic Uptake Inhibitors</a></li>
<li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li>
<li><a href="/mesh/adrenergic-antagonists">Adrenergic Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>50-55-5</td></tr><tr><th>Weight</th><td>Average: 608.6787<br>Monoisotopic: 608.273380888</td></tr><tr><th>Chemical Formula</th><td>C<sub>33</sub>H<sub>40</sub>N<sub>2</sub>O<sub>9</sub></td></tr><tr><th>InChI Key</th><td>QEVHRUUCFGRFIF-MDEJGZGSSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(3,4,5-trimethoxyphenyl)carbonyloxy]-3,13-diazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-2(10),4,6,8-tetraene-19-carboxylate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00206.gif?1265922771">show</a>(10.3 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Yohimbine Alkaloids</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Yohimbine Alkaloids</td></tr><tr><th>Alternative parents</th><td>Corynanthean-type Alkaloids; Beta Carbolines; Gallic Acid and Derivatives; M-methoxybenzoic Acids and Derivatives; P-methoxybenzoic Acids and Derivatives; Benzoic Acid Esters; Indoles; Benzylethers; Benzoyl Derivatives; Anisoles; Alkyl Aryl Ethers; Dicarboxylic Acids and Derivatives; Piperidines; Pyrroles; Carboxylic Acid Esters; Tertiary Amines; Polyamines; Dialkyl Ethers; Enolates</td></tr><tr><th>Substituents</th><td>beta-carboline; pyridoindole; gallic acid derivative; m-methoxybenzoic acid or derivative; p-methoxybenzoic acid or derivative; benzoate ester; benzylether; indole; indole or derivative; benzoic acid or derivative; phenol ether; anisole; benzoyl; alkyl aryl ether; piperidine; benzene; dicarboxylic acid derivative; pyrrole; tertiary amine; carboxylic acid ester; carboxylic acid derivative; dialkyl ether; polyamine; enolate; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the yohimbine alkaloids. These are compounds containing the pentacyclic yohimban skeleton.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Foe the treatment of hypertension</td></tr><tr><th>Pharmacodynamics</th><td>Reserpine is an adrenergic blocking agent used to treat mild to moderate hypertension via the disruption of norepinephrine vesicular storage. The antihypertensive actions of Reserpine are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral resistance.</td></tr><tr><th>Mechanism of action</th><td>Reserpine's mechanism of action is through inhibition of the ATP/Mg<sup>2+</sup> pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>62%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>Reserpine is extensively metabolized to inactive compounds. It is slowly excreted via the urine and feces.</td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Possible human carcinogen. May cause reproductive harm. ORL-RAT LD<sub>50</sub> 420 mg/kg; IPR-RAT LD<sub>50</sub> 44 mg/kg; IVN-RAT LD<sub>50</sub> 15 mg/kg; ORL-MUS LD<sub>50</sub> 200 mg/kg; SCU-MUS LD<sub>50</sub> 52 mg/kg; IPR-RBT LD<sub>50</sub> 7 mg/kg</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9216</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9257</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6549</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7928</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.75</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5194</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8859</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7065</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.8965</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9384</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7062</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9439
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1297 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7505
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6194
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li>
<li>Eli lilly and co</li>
<li>Bowman pharmaceuticals inc</li>
<li>Bristol myers squibb co</li>
<li>Barr laboratories inc</li>
<li>Bell pharmacal corp</li>
<li>Cm bundy co</li>
<li>Elkins sinn div ah robins co inc</li>
<li>Everylife</li>
<li>Halsey drug co inc</li>
<li>Impax laboratories inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Marshall pharmacal corp</li>
<li>Mk laboratories inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pharmavite pharmaceuticals</li>
<li>Purepac pharmaceutical co</li>
<li>Private formulations inc</li>
<li>Rexall drug co</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Solvay pharmaceuticals</li>
<li>Tablicaps inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Valeant pharmaceuticals international</li>
<li>Watson laboratories inc</li>
<li>West ward pharmaceutical corp</li>
<li>Whiteworth towne paulsen inc</li>
<li>Lannett co inc</li>
<li>Panray corp sub ormont drug and chemical co inc</li>
<li>Vale chemical co inc</li>
<li>Vitarine pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Apotheca Inc.</li>
<li>C.O. Truxton Inc.</li>
<li>Carlisle Laboratories Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>Eon Labs</li>
<li><a href="http://www.hhlabs.com">H and H Laboratories</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Quality Research Pharmaceutical Inc.</li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00841">Dobutamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB06704">Iobenguane</a></td><td>May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01365">Mephentermine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00610">Metaraminol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00723">Methoxamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00388">Phenylephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Reserpine may increase the adverse/toxic effects of tetrabenazine as they have similar pharmacologic properties. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Reserpine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Addition of Reserpine to Tranylcypromine therapy may induce paradoxical Reserpine effects, including peripheral hypertension and central exciation. Close monitoring for adverse effects is required. Addition of Tranylcypromine to Reserpine therapy may be less of a concern. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Reserpine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Magnesium, potassium and zinc needs increased.</li>
<li>Take with food to reduce irritation. Avoid alcohol.</li></ul></td></tr></tbody></table>